Discrepancies among studies in HER2 low patients might be attributed to varying methods of HER2 status assessment, differences in patient populations (such as distinct patient and tumor characteristics), and diverse clinical management approaches (including different types of CDK4/6i, backbone endocrine therapy or differing subsequent lines of therapy). Here, ERBB2 is linked to neoplasm.